Coverage
-
March 30, 2015
An Ohio federal judge on Friday dismissed False Claims Act allegations that Bristol-Myers Squibb Co. and Otsuka America Pharmaceutical Inc. defrauded the government and used kickbacks to promote off-label sales of antipsychotic drug Abilify, but left intact whistleblowers' retaliation claims against BMS.
1 other articles on this case.
View all »